Platelet function in ischemic heart disease

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 2, 2013, Pages 166-174

  Picker, Susanne M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

acute coronary syndromes; platelet function; platelet receptor blockade

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CALCIUM; CANGRELOR; CD36 ANTIGEN; CLOPIDOGREL; COLLAGEN; CYCLIC AMP; FIBRONECTIN; GLYCOPROTEIN IIB; INTERCELLULAR ADHESION MOLECULE 1; LAMININ; PADGEM PROTEIN; PHOSPHOLIPASE A2; PROTEINASE ACTIVATED RECEPTOR; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBOSPONDIN; TICLOPIDINE;

ARTERY THROMBOSIS; ARTICLE; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; CALCIUM CELL LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ABSORPTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MICROCIRCULATION; PATHOPHYSIOLOGY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RESPIRATORY ALKALOSIS; REYE SYNDROME; STABLE ANGINA PECTORIS; SUBENDOTHELIUM; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; MYOCARDIAL ISCHEMIA; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 84873406564     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318279b78a     Document Type: Article

References (68)

1. Gawaz M. Blood Platelets. Physiology, Pathophysiology, Membrane Receptors, Antiplatelet Principles, and Therapy for Atherothrombotic Diseases. Stuttgart, Germany: Georg Thieme Verlag; 2001.
2. Ueno M, Kodali M, Tello-Montoliu A, et al. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb. 2011;18:431-442.
3. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61:498-511.
4. Dorsam RT, Kunapuli SP. Central role of the P2-12 receptor in platelet activation. J Clin Invest. 2004;113:340-345.
5. Gawaz M, Reininger A, Neumann FJ. Platelet function and plateletleukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res. 1996;83:341-349.
6. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229-237.
7. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
8. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
9. Reininger AJ, Agneskirchner J, Bode PA, et al. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surfaceabsorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor - results from patients with acute myocardial infarction and healthy controls. Thromb Haemost. 2000;83:217-223.
10. Schrör K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349-356.
11. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234SY264S.
12. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: To halve and halve not. J Am Coll Cardiol. 2000;35:1808-1812.
13. OPTIMIZE-HF Investigators, Fonarow GC, Abraham WT, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): Rationale and design. Am Heart J. 2004; 148:43-51.
14. Levy PD, Nandyal D, Welch RD, et al. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2010;159:222-230.
15. RESPONSE Investigators, Gurbel PA, Bliden KP, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation. 2010;121: 1188-1199.
16. CHARISMA Investigators, Berger PB, Bhatt DL, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010; 121:2575-2583.
17. Hart RG, Bhatt DL, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: Subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25:344-347.
18. Howard PA. Guidelines for stroke prevention in patients with atrial fibrillation. Drugs. 1999;58:997-1009.
19. Mant J, Hobbs FD, Fletcher K, et al BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet. 2007;370:493-503.
20. Hopps S, Marcy TR. Warfarin versus aspirin: Using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation. Consult Pharm. 2009;24:841-844.
21. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;(4):CD000187.
22. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
23. Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation. 2005;111:267-271.
24. Tantry US, Bliden KP, Gurbel PA. Prasugrel. Expert Opin Investig Drugs. 2006;15:1627-1633.
25. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25:15-19.
26. CLEAR PLATELETS Investigators, Gurbel PA, Bliden KP, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-1159.
27. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120: 311-321.
28. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: 3171-3175.
29. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost. 2007;97:282-287.
30. CLEAR PLATELETS 1b Investigators, Gurbel PA, Bliden KP, et al. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: Results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol. 2006;48: 2186-2191.
31. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-1750.
32. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug "resistance". Part 1: mechanisms and clinical measurements. Nat Rev Cardiol. 2009;6: 273-282.
33. CHAMPION Investigators, Harrington RA, Stone GW, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318-2329.
34. CHAMPION-PLATFORM Investigators, Bhatt DL, Lincoff AM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330-2341.
35. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-142. Erratum in J Clin Pharmacol. 2010;50:483.
36. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377-384.
37. PRINCIPLE-TIMI 44 Investigators, Wiviott SD, Trenk D, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
38. TRITON-TIMI 38 Investigators, Montalescot G, Wiviott SD, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731.
39. Freeman MK. Thienopyridine antiplatelet agents: focus on prasugrel. Consult Pharm. 2010;25:241-257.
40. JUMBO-TIMI 26 Investigators, Wiviott SD, Antman EM, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2-12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-3373.
41. PLATO Investigators, Held C, Asenblad N, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672-684.
42. Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19. 2 genotype: first experience in patients. J Thromb Haemost. 2010;8:43-53.
43. INNOVATE-PCI Investigators, Welsh RC, Rao SV, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2-12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention (INNOVATE PCI trial). Circ Cardiovasc Interv. 2012;3: 336-346.
44. Stone GW, Grines CL, Cox DA, et al Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346: 957-966.
45. Topol EJ, Moliterno DJ, Herrmann HC, et al TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
46. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
47. Cannon CP, Weintraub WS, Demopoulos LA, et al TACTICS Investigators (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Myocardial Infarction 18. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
48. IMPACT-II Investigators, Blankenship JC, Sigmon KN, et al. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT-II Trial - (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II Trial). Am J Cardiol. 2001; 88:969-973.
49. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126:875-910.
50. EPIC Investigators, Topol EJ, Califf RM, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet. 1994;343: 881-886.
51. Montalescot G, Barragan P, Wittenberg O, et al The ADMIRAL Investigators. Abciximab Before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
52. The ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet. 2000;356:2037-2044. Erratum in Lancet. 2001;357:1370
53. STOP-AMI Investigators, Schömig A, Kastrati A, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction. N Engl J Med. 2000;343:385-391.
54. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100:799-806.
55. Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. J Cardiovasc Pharmacol. 2005;45:389-395.
56. Vilahur G, Casaní L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost. 2007;98:662-669.
57. Belhassen L, Pelle G, Dubois-Rande JL, et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003;41:1198-1204.
58. Verbeuren TJ, Vallez MO, Lavielle G, et al. Activation of thromboxane receptors and the induction of vasomotion in the hamster cheek pouch microcirculation. Br J Pharmacol. 1997;122:859-866.
59. Chintala M, Strony J, Yang B, et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 2010;30:2143-2149.
60. TRA-PCI Investigators, Becker RC, Moliterno DJ, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919-928.
61. LANCELOT-ACS Investigators, O'Donoghue ML, Bhatt DL, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: The lessons from antagonizing the cellular effects of ThrombinYAcute Coronary Syndromes Trial. Circulation. 2011;123:1843-1853.
62. TRACER Investigators, Tricoci P, Huang Z, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20-33.
63. ESPS 2 Investigators, Diener HC, Cunha L, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
64. Diener HC, Sacco RL, Yusuf S, et al Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebocontrolled study. Lancet Neurol. 2008;7:875-884. Erratum in Lancet Neurol. 2008;7:985.
65. Jeong YH, Hwang JY, Kim IS, et al ACCEL-AMI Investigators. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010;3: 17-26.
66. DECREASE Investigators, Lee SW, Park SW, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J. 2010;159:284-291.
67. Kozlowski EO, Pavao MS, Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost. 2011;1111:1538-7836.
68. Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and antagonism: Emerging approaches for the prevention of intravascular thrombosis. Thromb Res. 2008;122:786-803.